Mesothelioma is a rare and tough cancer to treat and is usually linked to asbestos exposure. Scientists are continually exploring new ways to treat it, and one promising method is using the combination of the two drugs nivolumab and ipilimumab. A new study looks at what these drugs do and shares some real-world information. The results show how researchers are helping people with mesothelioma. Mesothelioma is a type of cancer that shows up in the lining around certain areas of the body including the lungs, abdomen, heart, and testicles. It is connected to asbestos exposure, which is a harmful substance that was once used in construction, steel, and other industries.
Researchers have been testing a combination of two drugs – nivolumab and ipilimumab – as a new way to treat mesothelioma. These drugs work by helping the immune system identify cancer cells and attack them. Researchers studied 184 patients with mesothelioma. All the patients were treated with nivolumab and ipilimumab between January 2021 and August 2022. They checked how well the treatment worked and if there were any problems. Around 30 percent of the patients experienced some serious side effects. These are known as treatment-related adverse events, or TRAEs. Unfortunately, the side effects experienced by patients led 23 percent of them to stop treatment early.
The combination treatment showed good results in the real world. About 22 percent of patients had their tumors respond to the treatment, known as overall response rate or ORR. The average time the treatment worked was 5.7 months. After 12 weeks, more than half of the patients had their disease under control. The treatment also helped survival time in patients. On average, patients went about 5.5 months without their disease progressing or getting worse. This is also called progression-free survival. Their overall survival ended up being around 14.1 months.
Using nivolumab and ipilimumab together seems to be helpful for the treatment of mesothelioma. It makes the cancer respond, keeps it under control, and helps people live longer. It is also important to note that it can cause serious side effects, leading some to stop treatment. Researchers are learning how to best mitigate these side effects. As we understand more, we can improve the treatment to make it safer and even more effective for people fighting mesothelioma.
Cancer treatment like immunotherapy is crucial to the improvement of mesothelioma and other hard-to-treat cancers. These drugs improve the ability of the immune system, allowing for the body to identify and target cancer cells that it would not normally see. This is especially important for mesothelioma because it is very hard to treat and can hide from the immune system. Improving the immune response to mesothelioma could make other treatments more effective, allowing for a synergistic effect between treatments, making a more effective treatment regimen for the disease.
Skip to content